Status:
COMPLETED
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.
Eligibility Criteria
Inclusion
- Men and women age ≥18 to ≤65 years with acute schizophrenia
- Provision of written informed consent prior to enrolment
Exclusion
- Meeting the criteria for any other (than schizophrenia) psychotic disorder not in full remission, concomitant organic mental disorder or mental retardation
- Patients with substance dependence
- Female patients who are pregnant, lactating or at risk of pregnancy
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00254787
Start Date
June 1 2005
End Date
January 1 2006
Last Update
June 11 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany
2
Research Site
Cologne, Germany
3
Research Site
Essen, Germany
4
Research Site
Hamburg, Germany